# A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain

> **NCT03967327** · PHASE3 · UNKNOWN · sponsor: **Mundipharma (China) Pharmaceutical Co. Ltd** · enrollment: 194 (estimated)

## Conditions studied

- Cancer Pain

## Interventions

- **DRUG:** Buprenorphine transdermal patches
- **DRUG:** Morphine Sulfate Sustained-Release Tablet

## Key facts

- **NCT ID:** NCT03967327
- **Lead sponsor:** Mundipharma (China) Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-22
- **Primary completion:** 2020-12-20
- **Final completion:** 2020-12-31
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2019-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03967327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03967327, "A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03967327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*